Company intelligence / Profile preview

Samphire Group

London, United Kingdom

Ownership: Private
Employees: ~10
Development stage: Other

Overview

Samphire Neuroscience has conducted clinical trials demonstrating that its Nettle device offers clinically significant relief in period pain and mood symptoms for PMS and PMDD, showing reduced pain, improved mood, and reduced brain fog within a month of use; clinical data underpinned their successful CE-mark application and strong early commercial adoption, with high demand and sold-out launches in the EU[7][1][8].

Therapeutic areas: Women's Health
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Samphire Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Samphire Group.

Explore the full profile